Logo

A case of refractory intestinal Behçet's disease treated with tocilizumab, a humanised anti-interleukin-6 receptor antibody

1, 2, 3

  1. Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.
  2. Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.
  3. Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China. hejing1105@126.com

CER10367 Submission on line
2017 Vol.35, N°6 ,Suppl.108 - PI 0116, PF 0118
Case Report

Rheumatology Article

 

Abstract

We describe a young female patient who had refractory intestinal Behçet’s disease that responded to tocilizumab, a humanised anti-interleukin-6 receptor antibody. The patient had suffered from long disease activity courses and was treated with multiple medications, and the disease became refractory when immunosuppressants (e.g., thalidomide, sulfasalazine and azathioprine) were limited for poor remission, methylprednisolone pulse therapy, cyclophosphamide, and biological agents (e.g., adalimumab or infliximab) were restricted due to side effects after administration. Therefore, tocilizumab was considered as a therapeutic option and the symptoms resolved during 9 months of administration. Tocilizumab may be a good choice for intestinal Behçet’s disease refractory to conventional treatment.

PMID: 28980896 [PubMed]

Received: 25/02/2017 - Accepted : 21/06/2017 - In Press: 21/09/2017 - Published: 27/11/2017